Patents Assigned to PIKAMAB, INC.
  • Publication number: 20140170670
    Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on an Fc?RIIA polymorphism, or an Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and an Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.
    Type: Application
    Filed: October 28, 2013
    Publication date: June 19, 2014
    Applicant: Pikamab, Inc.
    Inventor: Vijay Ramakrishnan
  • Patent number: 8592149
    Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: November 26, 2013
    Assignee: PIKAMAB, Inc.
    Inventor: Vijay Ramakrishnan
  • Publication number: 20120039871
    Abstract: Methods and materials are provided for selecting and/or treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIB polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIB polymorphism, for treatment with a therapy including an antibody therapy such as rituximab. Methods are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIB polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIB polymorphism.
    Type: Application
    Filed: November 7, 2008
    Publication date: February 16, 2012
    Applicant: PIKAMAB, INC.
    Inventor: Vijay Ramakrishnan
  • Publication number: 20120030144
    Abstract: The present disclosure relates generally to methods for doing business by using one or more biomarkers (e.g., a subject's genetic polymorphisms) to improve the research, development, testing, commercialization and/or marketing of a drug by identifying those subjects for whom the particular drug is likely to be more effective.
    Type: Application
    Filed: November 7, 2008
    Publication date: February 2, 2012
    Applicant: PIKAMAB, INC.
    Inventor: Vijay Ramakrishnan
  • Publication number: 20100291549
    Abstract: Methods and materials are provided for determining the responsiveness of a subject to a therapy, such as an antibody therapy and for selecting and/or for treating a subject based on a Fc?RIIA polymorphism, or a Fc?RIIIA polymorphism, or both an Fc?RIIA polymorphism and a Fc?RIIIA polymorphism, including where the treatment is an therapy, such as rituximab. Methods and materials are also provided for designing, making, screening, testing and/or administering antibodies as well as for optimizing antibody therapies based upon a subject's Fc?RIIA polymorphism, or Fc?RIIIA polymorphism, or both the Fc?RIIA polymorphism and the Fc?RIIIA polymorphism.
    Type: Application
    Filed: April 27, 2007
    Publication date: November 18, 2010
    Applicant: PIKAMAB, INC.
    Inventor: Vijay Ramakrishnan